Note that updated information regarding the quarantine of one lot of Isoproterenol Hydrochloride Injection USP was added to this advisory on March 26, 2012. Following our March 21, 2012, Notice to Hospitals and Notice to Healthcare Professionals , Health Canada is advising Canadians that Sandoz Canada Inc. will be voluntarily recalling a portion of one lot of 2 mg/mL (1 mL) Morphine Sulfate Injection (Lot CC2824 exp. 2014-12) from the Canadian market. The recall applies to all products that has been distributed to healthcare providers. The recall is in light of a report from a Toronto hospital that found one box labelled as morphine ampoules (vials) incorrectly contained ampoules of isoproterenol. Sandoz has remaining inventory of the affected lot, which has not been distributed. In light of current supply constraints and to minimize the impact on Canadians, Sandoz Canada is currently inspecting its inventory of morphine packages from the affected lot to confirm that all of the morphine packages contain the correct product. Once Sandoz Canada has verified that all of the packages contain the correct product, the inventory will be clearly marked to indicate it has been inspected and can be released on the market. Products that are currently in distribution and that are being recalled will not be re-released. Healthcare professionals and Canadians are also advised that, further to our March 21 Notices, the quarantine of one lot of 0.2 mg/mL (1 mL) Isoproterenol Hydrochloride Injection USP (Lot CB8787 exp. 2012-11) has been lifted. Healthcare facilities with this product in stock are advised that product from this lot can be released for use as appropriate.
RecallTracker